Evidence map›Paper›PMID 42521517›Full record

ArticleEuropean urology2026

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.

Amar U Kishan, Yilun Sun, Christopher C Parker, Paul Sargos, Matthew Sydes, Sylvie Chabaud, Meryem Brihoum, Stephane Supiot, Igor Latorzeff, Stephane Guerif and 26 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Amar U KishanDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: aukishan@mednet.ucla.edu.
Yilun SunDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Christopher C ParkerThe Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
Paul SargosInstitut Bergonié, Bordeaux, France.
Matthew SydesMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Sylvie ChabaudClinical Research Department, Centre Léon Bérard, Lyon, France.
Meryem BrihoumUnicancer, Paris, France.
Stephane SupiotInstitut de Cancérologie de l'Ouest, Saint Herblain, Nantes, France.
Igor LatorzeffRadiation Deparment Onco-Urology and BrainClinque Pasteur, Groupe Orion1 rue de la petite vitesse, 31300 Toulouse, France.
Stephane GuerifCentre Hospitalier Universitaire de Poitiers, Poitiers. France.
Tahmineh Romero KalbasiDepartment of Medicine Statistical Core, University of California, Los Angeles, Los Angeles, CA, USA.
Michael L SteinbergDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Luca F ValleDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Kekoa TaparraDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA; School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.
Matthew J FarrellDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Jonathan E ShoagDepartment of Urology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Jorge A GarciaDepartment of Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Jason R BrownDepartment of Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Matthew B RettigDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Adam E SingerDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Nikita BacligDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Robert E ReiterDepartment of Urology, University of California, Los Angeles, Los Angeles, CA, USA.
Scott EggenerDepartment of Urology, University of California, Los Angeles, Los Angeles, CA, USA.
Wayne BrisbaneDepartment of Urology, University of California, Los Angeles, Los Angeles, CA, USA.
Soumyajit RoyDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Angela Y JiaDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Ting Martin MaDepartment of Radiation Oncology, University of Washington, Seattle, WA, USA.
Nicholas G NickolsDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA; Department of Radiation Oncology, Greater Los Angeles VA, Los Angeles, CA, USA.
Jason A EfstathiouDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
James J DignamDepartment of Public Health Sciences, University of Chicago, Chicago, IL, USA; NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
Wendy F SeiferheldNRG Oncology Statistics and Data Management Center, Philadelphia, PA.
Alan PollackDepartment of Radiation Oncology, Miller School of Medicine and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Howard M SandlerDepartment of Radiation Oncology, Oregon Health and Sciences University, Portland, Oregon, USA.
Paul L NguyenDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA.
Pascal PommierClinical Research Department, Centre Léon Bérard, Lyon, France; Department of Radiotherapy, Institut Curie, Paris, France.
Daniel E SprattDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Funding

Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mei-Yin C Polley · 2014 to 2026
$146.4M
NSABP Foreign AccrualsU10CA037377 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WOLMARK, NORMAN · 1985 to 2014
$116.5M
Reducing toxicity from prostate cancer radiotherapy through genetics and technologyR37CA292795 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Amar U Kishan · 2024 to 2026
$1.1M
NCI NIH HHS R37 CA292795NCI NIH HHS U10 CA037377NCI NIH HHS U10 CA180822
6 · The paper itself

Abstract

BACKGROUND AND

objectiveA recent individual patient data (IPD) meta-analysis of randomized trials found a limited overall survival (OS) and metastasis-free survival (MFS) benefit to the addition of hormonal therapy (HT) to postoperative radiotherapy for prostate cancer in patients with pre-radiotherapy prostate-specific antigen (PSA) ≤0.5 ng/ml. We evaluated whether the OS and MFS benefits of adding HT might be significantly modified by an increasing count of adverse pathological features (adverse feature count [AFC]).

methodsWe obtained IPD from five randomized phase 3 trials of postoperative radiotherapy ± HT. AFC was prospectively defined as the sum (0-4) of grade group 4-5 disease, seminal vesicle invasion, positive surgical margins, and extracapsular extension. Intention-to-treat one-stage meta-analytical models were used. We also evaluated the interaction of the benefit of HT with a restricted score comprising only GG4-5 and seminal vesicle invasion (range 0-2), as a pre-specified sensitivity analysis. KEY FINDINGS AND LIMITATIONS: We included IPD from 4781 patients with a median follow-up of 9.1 yr. AFC was independently prognostic for OS and MFS. However, AFC did not significantly modify the OS benefit of HT (interaction hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.79-1.10; p = 0.4) or MFS benefit (interaction HR, 0.88; 95% CI, 0.77-1.01; p = 0.08). Results were similar when AFC was analyzed categorically and in high-risk subsets, and when the restricted AFC score was used. CONCLUSIONS AND CLINICAL IMPLICATIONS: Overall, the data suggest that although adverse pathological features are prognostic, they do not appear predictive of HT benefit after postoperative radiotherapy, which is relevant for patients with a PSA ≤0.5 ng/ml before radiation.

Indexed as

Hormonal therapyProstrateRadiation

Identifiers

PMID42521517
PMCPMC13602305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.